Ingrid Adams, now 68, has been coping with metastatic lung cancer for more than a decade. Standard treatment — including chemotherapy and radiation therapy — kept her disease under control for a while ...

Taletrectinib is now a preferred treatment for advanced ROS1-positive NSCLC, effective in first-line and subsequent therapies, especially for brain metastases. TRUST-I and TRUST-II trials showed high ...

Taletrectinib, a next-generation TKI, is approved for ROS1-positive NSCLC, showing high ORR and durable responses in clinical trials. TRUST-I and TRUST-II trials demonstrated efficacy in both ...

An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing. ROS1-positive non-small cell lung cancer, a ...

A new study shows that three common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be ...

The FDA approved taletrectinib (Ibtrozi)-- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell ...

Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients. Dr. Geoffrey Liu, a senior scientist at Princess Margaret ...

Through an integrated molecular- and histopathology-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase ...

In summary, the study by Lim et al 8 adds another highly effective agent to the growing roster of TKIs for advanced ROS1-positive NSCLC. However, the study also creates a new dilemma in the field, ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...